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Purpose: To analyse the pattern of use and cost of antihypertensive drugs in new users in an
Italian population, and explore the patient/treatment factors associated with the risk of
therapy discontinuation.
Patients and methods: In this retrospective study, information was collected from a popula-
tion-based electronic primary-care database. Persistence with medication use 1 year from therapy
initiation was evaluated for each user using the gap method. Each new user was classified
according to his/her pattern of use as: “continuer”, “discontinuer” “switching” or “add-on”.
A Cox regression model was used to analyse the factors influencing therapy discontinuation.
Primary-care costs comprised specialists’ visits, diagnostic procedures and pharmacologic
therapies.
Results: Among 14,999 subjects included in persistence analyses, 55.1% of cases initially started
on monotherapy were classified as discontinuers vs 36.5% of cases taking combination therapy
(42.3% vs 32.7%, respectively, for free and fixed combinations, P < 0.01). Old age, high
cardiovascular risk and being in receipt of fixed-combination therapy were associated with greater
persistence. Overall, the primary-care cost/person/year of hypertension management was ~€95.3
(IQR, 144.9). The monotherapy cost was €88 per patient (IQR, 132.9), and that for combination
therapy was €151±148.3. The median cost/patient with a fixed combination was lower than that for
a free combination (€98.4 (IQR, 155.3) and €154.9 (IQR, 182.6), respectively).
Conclusion: The initial type of therapy prescribed influences persistence. Prescribing fixed
combinations might be a good choice as initial therapy.
Keywords: drug-utilization, adherence, fixed combination, hypertension
Introduction
Hypertension affects 31.1% of the global population (1.4 billion people) and results
in 9.4 million deaths every year.1,2 Pharmacologic treatment can be very successful
with the potential to reduce blood pressure (BP) to recommended levels in almost
all patients (<140/90 mmHg or <130/80 mmHg for patients with diabetes mellitus
or chronic kidney disease). Monotherapy fails to control BP in ~50% of patients.
Hence, national and international guidelines suggest starting therapy with combina-
tions of more than one antihypertensive drug, which increases the complexity of the
therapeutic regimen.3
Therapy using a combination of antihypertensive drugs offers an advantage over
monotherapy (at least in part) due to the: (i) different sites of action of each drug;
(ii) lower risk of adverse events. It is important for patients to take their
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medications appropriately and continue to take them long
term.4 However, poor adherence and persistence in taking
medications are common problems in hypertensive
patients, partly because of complex treatment regimens
and high pill burdens. These factors result in sustained
periods of uncontrolled hypertension, leading to disease
progression and the associated economic consequences.
Various strategies have been implemented to
improve compliance with drug regimens. A combina-
tion of two pharmacologic agents in a single medicinal
product has been available for hypertension therapy
since the mid-1960s. Nowadays, numerous fixed-dose
combinations (hereafter termed “fixed combinations”)
are available for the treatment of hypertension and
other chronic diseases with high risks for morbidity
and mortality.5,6
In recent years, fixed combinations have acquired an
important role in hypertension management.7–9 Guidelines
set in 2018 by the European Society of Hypertension
(ESH)/European Society of Cardiology (ESC) stated that
fixed combinations can be used as first as well as second-
line therapies to achieve the recommended BP target.3 More
than 27 fixed combinations are available for daily use in
Italy. Of these, 18 consist of an angiotensin-converting
enzyme inhibitor (ACEI) and a diuretic or calcium-channel
blocker (CCB); 9 consist of an angiotensin-receptor blocker
(ARB) and a diuretic or a CCB.
Data on pharmacy claims have been suggested to be
powerful tools to analyze compliance with antihyperten-
sive therapy.10,11 However, studies that evaluate the ther-
apeutic approach to hypertension in primary care in Italy
are lacking.
We investigated the prescription patterns for hyperten-
sive patients in a real-world practice and whether drug
combinations improve persistence with drug therapy.
Furthermore, we discussed some aspects related to legal
authorization of fixed combinations.
Materials And Methods
Study Design And Data Sources
This was a retrospective cohort study on the pattern of use of
antihypertensive drugs in primary-care settings in the
Campania region of southern Italy. The study was carried out
according to Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) guidelines.
Data were retrieved from a population-based database for
general practitioners (COMEGEN Social Cooperative
Society) which oversees ~190,000 subjects.12 All participating
general practitioners use the same software to record data
during their daily practice, and receive formal and periodic
training for data entry (Millewin; Millenium Dedalus,
Florence Italy). For the present study, data were retrieved
using an encrypted patient code linking demographic details
with medical diagnoses, drug prescriptions, diagnostic tests
(with their relevant values) and date of death. All diagnoses
were coded according to the International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM).
Drugs were coded according to the Anatomical Therapeutic
Chemical (ATC) Classification System (ATC/Defined Daily
Doses methodology). The influence of dosage forms was not
the focus of our study. The term “pill”, even though it is not a
standard term employed by the European Directorate for the
Quality of Medicines, was used to identify the solid oral
dosage forms used by patients regardless the type of pharma-
ceutical dosage form (e.g., tablets, capsules) or release profile
(e.g., immediate, prolonged).13
The quality characteristics of this data source have been
described.14 COMEGEN has been used to provide drug-
utilization information and to undertake studies.15–19 This
automated system is anonymous so, according to the Italian
Data Protection Authority, neither Ethical Committee
approval nor informed consent were required for our study.20
Our research protocol adhered to the tenets of the Declaration
of Helsinki and its amendments.
Case Definitions
All patients with at least one prescription of an antihyperten-
sive drug were defined as “users” or “cases”. Antihypertensive
drugs were classified as belonging to C03 (diuretics), C07
(beta-blockers), C08 (CCBs), C09 (agents acting on the
renin–angiotensin system) groups of the ATC Classification
System.
The target population was classified into two groups:
“prevalent” cases and “incident” cases (cases with no
antihypertensive prescriptions during the 365 previous
days). The index date was the date of the first
prescription.
The study period was from 1 January 2010 to
31 December 2015. The year 2010 was the reference for
selecting incident cases with an index prescription in 2011.
2011–2014 was the “recruitment” period of the study popula-
tion (identification of prevalent cases and incident cases). The
year 2015 was used to follow-up incident cases with an index
prescription in 2014.
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Outcomes
The first prescriptions for incident cases were analyzed. To
identify the first-line therapeutic approach, the number and
type of antihypertensive drugs were recorded, and incident
cases in monotherapy and combination therapy were identi-
fied. That is: cases in monotherapy receiving a prescription of
only one drug, including diuretics (ATC: C03), beta-blockers
(ATC: C07), CCBs (ATC: C08), ACEIs (ATC: C09AA),
angiotensin II receptor antagonists (ATC: C09CA); cases in
fixed-combination therapy receiving products belonging to
C07BB, C07CB, C07FB, C09BA, C09BB, C09DA, or
C09DB ATC subgroups (Appendix); cases in free-combina-
tion therapy receiving two drugs belonging to C03 and/or
C07 and/or C08 and/or C09AA and/or C09CA ATC groups;
cases in “multiple mix” combinations receiving two or more
fixed combinations belonging to C09BA, C09BB, C09DA or
C09DB ATC subgroups and/or and free combinations of two
or more drugs belonging to C03 and/or C07 and/or C08 and/
or C09AA and/or C09CA ATC groups.
Concomitant therapy with anti-diabetes agents (ATC:
A10), lipid-lowering drugs (ATC: C10), antiplatelets
(ATC: B01AC) and hospitalizations for the diagnosis of
acute myocardial infarction (ICD 9 CM: 410–414), con-
gestive heart failure (ICD 9CM: 428) and cerebrovascular
disease (ICD 9 CM: 430–438) were analyzed.
Medication Persistence 1 year after therapy initiation
was evaluated according to the International Society of
Pharmacoeconomics and Outcome Research definition21
Recently, the European Society of Patient Adherence and
Compliance developed a Taxonomy of Adherence. This
defines medication adherence “as the process by which
patients take their medication as prescribed” and subdi-
vides adherence into three essential elements to capture the
sequence of events that must occur for a patient to experi-
ence the optimal benefit from his/her prescribed treatment
regimen: initiation, implementation, and discontinuation.
The present study focused on the discontinuation phase
(medication persistence)22 Medication persistence was
assessed using the gap method. A gap was defined as the
period during which no medication is available to the
patient. A user of antihypertensive drugs was considered
to be a “discontinuer” if a gap of >60 days between two
prescriptions was recorded. The number of days of avail-
able medication (days of therapy) was estimated based on
the pill number. These assumptions are based on studies
undertaken on antihypertensive drugs in an identical
setting.23,24 Only the number of days of therapy from the
prescription dispensed most recently was used to evaluate
the gap. Subjects were censored if the gap allowed was
exceeded without purchasing a new prescription or upon
reaching the end of the follow-up period (365 days after
the index date). As described by Halpern and colleagues25
persistence in the separated-drugs cohort was assessed as
“therapy persistence” (i.e., continuation with any antihy-
pertensive medication was sufficient to be considered as
persistent).
Each incident user was classified according to his/her
pattern of use as: “continuer”, “discontinuer”, “switching”
or “add-on”. A “spot user” (only one prescription during
the study period) and multiple mix (due to the complexity
of the regimen) were excluded from the analysis of
persistence.
Cost Analyses
Cost analyses were carried out on incident cases. The
methodology used for cost assessment was bottom–up
because this methodology values each cost component
for an individual patient. This approach enabled statistical
analyses aimed at the detection of cost differences among
patients and among cost components. For each type of
therapy, primary-care costs were expressed as the cost of
hypertension management per person year of follow-up.
They included specialists’ visits, diagnostic procedures,
laboratory costs, and pharmacologic therapies quantified
according to the Italian National Health Service (NHS) by
means of charges pertaining in 2015.
Cost analyses were conducted from the perspective of
the third-party payer, the NHS which, in Italy is in charge
of financing and providing healthcare services.
Costs are expressed in terms of median patient cost/
year, and interquartile range (IQR), stratified by the first-
line approach (monotherapy; free combination; fixed com-
bination). The total cost was computed as the sum of the
different cost items (drugs, visits, procedures). Values
were expressed in Euros at the time of the analyses.
Statistical Analyses
Data are the mean ± standard deviation for continuous
variables or as absolute and relative frequencies for catego-
rical variables. The chi-square test and analysis of variance
were undertaken to determine the difference between cate-
gorical and continuous variables. Cox regression models
estimated the likelihood of non-persistence over 1 year
after therapy initiation, and evaluated the factors influen-
cing the probability of discontinuation. Hazard ratios (HRs)
Dovepress Putignano et al
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and 95% confidence intervals (95%CIs) were calculated to
assess crude and adjusted associations for all covariates.
Cost data were skewed, and the nonparametric Kruskal–
Wallis test was used to examine significant differences in
median values across different therapy categories.
Data management was undertaken with SQL server v2018
(Microsoft, Redmond, WA, USA). Analyses were carried out
using SPSS v17.1 (IBM, Armonk, NY USA). P < 0.05 was
considered significant.
Results
During the study period, 46,482 subjects were identified as
chronic users of antihypertensive drugs (prevalent cases).
Overall, 18,504 (44.8% male) were incident cases.
Appendix Table 1 shows the main characteristics of the
cohort. For the overall cohort, the mean BP was 143±18.7/
87±11.1 mmHg. Also, 4474 subjects (24.2% of incident
cases) were also taking lipid-lowering drugs and 4027
(21.8% of incident cases) were also taking antiplatelets.
The most used first-line therapeutic approach was mono-
therapy (67.0% of subjects): 31.4% of cases in monother-
apy began with an ACEI, 25.8% with beta-blockers,
18.1% with diuretics and 24.7% with ARBs or CCBs.
Among subjects starting combination therapy, fixed com-
binations were the most used (60.0%).
During the 12 months after the index prescription,
51.8% of incident cases, of the total cohort, discontinued
the initial treatment, 19.3% remained with the same anti-
hypertensive drug, 20.2% switched to another antihyper-
tensive drug, and 8.6% received prescriptions for a new
drug in addition to the initial therapy (Appendix Table 1).
We found that 14,999 subjects (excluding spot therapy
and multiple-mix therapy) were included in the persistence
analysis. Overall, 55.1% of cases with initial monotherapy
were classified as discontinuers vs 36.5% of cases in
combination therapy (p < 0.001).
Among subjects starting with combination therapy, the
highest percentage of discontinuers was for free combina-
tions (42.3%) compared with fixed combinations (32.7%)
(p < 0.01) (Figure 1).
Cox regression analysis (Appendix Table 2) shows
that subjects in combination therapy were less likely to
be non-persistent compared with those in monotherapy.
In particular, subjects in free-combination therapy were
~17% less likely to have a period of discontinuation,
and subjects in fixed-combination therapy were ~43%
less likely to be non-persistent (free combination: HR,
0.83 [95%CI 0.77–0.90]; fixed combination: 0.57, 0.54–
0.61). With increasing age, the risk of non-persistent
therapies increased (40–49 years: HR, 0.74 [95%CI
0.69–0.80]; 50–59 years: 0.71, 0.66–0.76; 60–69 years:
0.64, 0.59–0.69; 70–79 years: 0.62, 0.57–0.67; 80 years:
0.68, 0.62–0.75); concomitant treatment with lipid-low-
ering drugs and/or antiplatelet therapy decreased the risk
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Figure 1 Pattern of persistence with monotherapy, fixed dose and free combination (prevalence, 95%CI).
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of non-persistence with therapy (0.83, 0.78–0.88; 0.75,
0.71–0.80) (Appendix Table 2).
Overall, the primary-care costs per person per year of
hypertension management were estimated to be €95.3
(IQR, 144.9). On average, monotherapy cost €88 per
patient (IQR, 132.9), whereas combination therapy cost
€151±148.3. The median cost per patient with a fixed
combination was lower than that of a patient with a free
combination, €98.4 (IQR, 155.3) and €154.9 (IQR, 182.6),
respectively. Figure 2 shows median costs stratified by
persistence patterns. Stratification of total costs, according
to the pattern of persistence and the prescribed combina-
tion (fixed vs free), showed that patients changing therapy
in the follow-up period (add-on and switchers) had the
highest direct costs for both combinations, followed by
the continuers for the fixed combination and discontinuers
for the free combination.
Discussion
This retrospective cohort study elicited several important
findings. ESH/ESC 2018 guidelines emphasize that mono-
therapy can reduce BP values efficaciously in a limited
number of patients, and that most of them require the
association of at least two drugs to achieve BP control.3
Our results showed that monotherapy was the most used
first-line therapeutic approach (72.5% of incident cases).
We found that 27.5% of incident cases were in combina-
tion therapy, and this was probably due to excessive
confidence in the efficacy of monotherapy, with conse-
quent scarce and insufficient use of combination therapy
in the hypertensive population.26
In the present study, ACEIs were the most used drugs in
monotherapy, a finding that is consistent with the literature.27
Indeed, studies have suggested that patients initiated on
ACEIs and beta-blockers have slightly better BP control.28
We showed that 50.0% of the study population discon-
tinued their initial treatment within 1 year, whereas 22% of
patients switched to another drug class during the same
period. Suboptimal adherence to medication-taking is fre-
quent in real-world practices: usually, ~50% of all pre-
scribed medications for chronic diseases are not taken as
prescribed.29,30
Focusing research on adherence to treatment is very
much a research focus currently.31,32 The factors under-
lying the lack of adherence to therapy are many and
varied.33,34 They are related to physicians’ behavior or to
the willingness of the patients to follow the prescriptions
or to the characteristics of the drugs (which are sometimes
impediments to correct long-term treatment).35,36
With regard to factors related to patients, concerns about
medications and their adverse effects should be noted, as well
as a lack of knowledge of their own disease and the presence
of comorbidities, which are accentuated in the presence of
socio-economic and psychological/cognitive limitations.37–41
Moreover, factors related to therapy, such as complexity and
multiple medications, must be taken into account.
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Figure 2 Annual primary-care costs (median and IQR) by drug cohort and persistence category.
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We showed that patients taking combination therapy
were less likely to be non-persistent compared with those
in monotherapy. These results are in accordance with data
from other studies carried out with the same methodology
in Italian settings.42,43 Interestingly, among subjects taking
combination therapy, a higher percentage of subjects in
free combination were discontinuers (42.3%) compared
with those in fixed combination (32.7%) (P < 0.01). The
persistence of patients with regard to antihypertensive
therapy may decrease with an increasing number of
drugs in multiple pill regimens. Furthermore, better per-
sistence has been associated with old age and greater
cardiovascular risk. The most persistent subjects were
those who received antiplatelets and/or lipid-lowering
drugs together with antihypertensive agents. That is,
greater persistence seems to be associated with greater
awareness of the risks related to the disease.
Fixed combinations have been developed to reduce the
pill burden for hypertensive patients. According to the
European regulatory framework, a fixed combination is a
medicinal product which contains at least two active sub-
stances combined to improve the therapeutic efficacy or
safety profiles in comparison with monotherapy44 In this
context, fixed combinations can be classified according to
three therapeutic goals: (a) add-on treatment of patients
whose disease is not controlled by existing therapies; (b)
substitution therapies in monitored patients to simplify the
multiple-drug daily regimen; (c) initial combination thera-
pies for treatment-naïve patients.
If the drug substances contained in a fixed combination
are not new, an abridged (or hybrid) application can be
followed to achieve the marketing authorization. In this
light, the authorization dossier is simplified. A full char-
acterization of physicochemical and technologic properties
must be provided to support the quality of the fixed
combination.
However, the preclinical and clinical data required by
regulatory agencies vary based on the complexity of
assessment of the efficacy–safety balance of the new
drug product (in addition to the established scientific and
clinical knowledge). Indeed, according to article 10b of
Directive 2001/83/EC, in the case of a fixed combination
for add-on treatments or treatments containing drug sub-
stances already present in authorized medicinal products
but not hitherto used in combination for therapeutic pur-
poses (e.g., initial combination therapies), the applicant
must include in the dossier the results of preclinical or
clinical studies to support the pharmacologic and medical
rationale of the combination and to determine the benefit–
risk balance on the basis of the desired therapeutic effect.
In the case of add-on treatment, the superiority of fixed
combinations compared with monotherapies should be
demonstrated. However, preclinical and clinical studies
on individual drug substances should not be provided
because data can be derived from already authorized med-
icinal products. Conversely, if the drug substances are
already being used in clinical practice as free-combination
or fixed-combination products (e.g., substitution thera-
pies), the preclinical and clinical studies required may be
simplified significantly and based on demonstration of
therapeutic equivalence. Indeed, bioequivalence studies
vs the free-combination or fixed-combination originator
can be accepted. Such studies are fundamental to support
substitution of monotherapies with fixed combinations.
Comparative efficacy studies of treatment strategies
using antihypertensive therapeutic classes in hypertension
control in primary care showed that patients beginning anti-
hypertensive therapy with a fixed combination had signifi-
cantly greater reductions in BP than patients initiated on a
free combination or monotherapy.34 By reducing the overall
pill burden and simplifying medication regimens, fixed com-
binations have been shown to improve medication compli-
ance and medication persistence in several studies.45–51 A
recent retrospective cohort study carried out in Canada
showed that patients taking a fixed combination had greater
rates of medication adherence than the free-combination
group (70% vs 42%, P < 0.01) and a significantly lower
risk of composite clinical outcomes, which may have been
related to better adherence to therapy.44
We also evaluated the primary-care costs of fixed and
free combinations. After 12-month follow-up, the fixed-
combination group had an annual mean cost per patient
lower than free combinations. Furthermore, for both drug
combinations, patient-changing therapy was the most
expensive. This reduction in healthcare costs is consistent
with the results observed in other reports. In a meta-ana-
lysis comparing annual healthcare costs of fixed vs free
equivalent combination regimens for hypertension treat-
ment, Sherrill et al estimated a $2039 reduction in all-
cause total costs and a $709 reduction in hypertension- and
cardiovascular-related costs in the fixed-combination
group.52
Combination therapy with a fixed combination may be
less costly than if the drugs are administered separately.
Furthermore, recently many fixed combinations have
become available as generic formulations in Italy, and
Putignano et al Dovepress
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this may encourage the use of the drugs used in fixed
combinations.
Strengths And Limitations Of Our Study
Our study was conducted in >170,000 subjects and cov-
ered a 5-year period. Only subjects living in the Campania
region and receiving prescriptions from general practi-
tioners belonging to the COMEGEN Medical Association
were included in analyses, so prescribing patterns may not
be fully representative of those in Italy. For assessment of
persistence, patients with at least one discontinuation epi-
sode were considered to be non-persistent. However, an
intrinsic limitation of retrospective analyses of databases
(such as COMEGEN) is that tracking the reason for the
discontinuation is not possible, such as whether disconti-
nuation was recommended by the clinician (e.g., a tem-
porary suspension due to an adverse reaction). Also,
pharmacy-refill records provide details only on whether
patients were dispensed their medication, and do not pro-
vide details on whether patients ingested their medications.
Healthcare databases can be used to support evaluation of
the use of drugs in real-world practice allowing tracing (over
time) of their type, mode and use. In particular, through
pharmaceutical prescriptions, it was possible to trace the
profiles of persistence to pharmacologic therapies.
Some factors not included in our analyses, such as
governmental regulation of prescribing, as well as mon-
itoring the drug-expenditure budget of general practi-
tioners and the pharmaceutical industry, could influence
the prescriber’s choice of therapeutic regimen. In addition,
it was not possible to assess the costs of hospital admission
or indirect costs because such information was scarce or
not available.
Conclusions
Our retrospective study presented the real-world results of
different regimens for hypertension treatment. We found
that use of a fixed combination improved persistence and
decreased healthcare costs compared with use of free
combinations. Use of a fixed combination provided an
important opportunity to improve the quality of hyperten-
sion treatment. Therefore, it is reasonable for physicians,
pharmacists and regulatory agencies to facilitate use of
fixed combinations for patients who need to take two or
more antihypertensive drugs. Nevertheless, the improve-
ment of persistence is a complex problem requiring a
multifactorial strategy, and simplification of therapy with
fixed formulations is a crucial aspect.
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